Before the opening bell, Immune Therapeutics, Inc. (OTCQB: IMUN) announced its entry into a binding letter of intent to acquire Chinese Chimeric Super Antigen Receptor T cell (CAR-T) cocktail therapy, pending immuno-oncology patents, manufacturing technology and clinical data regarding the aforementioned therapies from Super-T Cell Cancer Company (STCC), a newly-formed corporation. The technology outlined in […]
The Stocks To Buy Now Blog
Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.